-

Fujirebio Europe Launches the RoboBlot™ Instrument, a Fully Automated Solution for INNO-LIA® Score Assays

GENT, Belgium--(BUSINESS WIRE)--Fujirebio Europe announced today the commercial launch of the RoboBlot instrument, a closed system for the automated processing of the widely used INNO-LIA Score assays. The instrument is manufactured by Bee Robotics Ltd. and distributed by Fujirebio Europe. The system’s pre-programmed test protocols provide start-to-finish automation of strip-based INNO-LIA Score assays, from sample addition, over strip processing, image capture, to result interpretation and where applicable laboratory information system (LIS) communication.

“High throughput testing and more automation are an increasingly pressing need for laboratories. The typical drawbacks of manual testing, such as long hands-on time, inconsistent assay handling and issues with traceability, will become part of the past,” said Christiaan De Wilde, CEO at Fujirebio Europe. “The RoboBlot instrument will radically improve the laboratory workflow for our customers, from tedious manual or semi-automated work into fully automated testing.”

RoboBlot extends the range of automated solutions already offered by Fujirebio Europe for the INNO-LIA Score assay portfolio. It offers high-throughput testing, full automation with pipetting up to 50 samples and integrated camera for scanning and interpretation with Fujirebio LiRAS software, providing complete traceability with minimal hands-on time. It offers a customized fit with individual laboratory needs. Other automated solution for this portfolio is the TENDIGO®.

More information about RoboBlot can be found in our website and the instrument will be on display during the Medlab meeting from the 24th to the 27th of January 2022 in Dubai at the Fujirebio booth (booth Z5.C15)

Please contact your local sales representative for the availability of these products in your country.

About Fujirebio
Fujirebio is a global leader in the field of in vitro diagnostics (IVD) testing with more than 50 years’ experience in the conception, development, production and worldwide commercialization of robust IVD products. These span the range from specialized testing to fully automated routine clinical laboratory testing solutions covering a variety of disease states.

About Bee Robotics Ltd.
Founded in 1999, Bee Robotics Ltd. is a privately-owned company based in North Wales that has established a world-wide reputation as a leader in the field of design and manufacture of advanced liquid handling robotic solutions for laboratory automation. Today Bee Robotics Ltd. employs a highly skilled core team specialized in electronic, mechanical, robotics and software engineering that is involved from hardware and software design and prototyping, to development and manufacturing laboratory solutions.

Contacts

Christiaan De Wilde
CEO Fujirebio Europe
+32 9329 1703

FUJIREBIO EUROPE

Details
Headquarters: Tokyo, Japan
CEO: Goki Ishikawa
Employees: 1400
Organization: PRI


Contacts

Christiaan De Wilde
CEO Fujirebio Europe
+32 9329 1703

Social Media Profiles
More News From FUJIREBIO EUROPE

Fujirebio Acquires Plasma Services Group and Strengthens Its Position as Provider of Critical and High Quality Biological Raw Materials to the IVD and Life Science Industries

MALVERN, Pa. & TOKYO--(BUSINESS WIRE)--H.U. Group Holdings Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (hereinafter “Fujirebio”) today announced that Fujirebio Diagnostics, Inc., a subsidiary of Fujirebio, has acquired all shares of Plasma Services Group, Inc. (hereinafter “Plasma Services Group”). The transaction value has not been disclosed. Founded in 2004, Plasma Services Group has specialized in the collection, screening and supply of high quality and rare biological ma...

Fujirebio Announces Strategic Collaboration with Stanford Medicine to Advance Infectious Disease Research

TOKYO & SUNNYVALE, Calif.--(BUSINESS WIRE)--Fujirebio, a leading innovator in in-vitro diagnostics, today announced a collaboration with Stanford Medicine (Location: Palo Alto, California, USA) to advance research and innovation in the field of infectious disease testing. This collaboration aims to accelerate the adoption of ultrasensitive immunoassays that incorporate single-molecule counting technology developed by Fujirebio’s Silicon Valley wholly-owned subsidiary, Fluxus, Inc. Greater test...

Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G sTREM2 Assay for Research Use Only

GENT, Belgium & MALVERN, Pa. & TOKYO--(BUSINESS WIRE)--H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G sTREM2 assay for the fully automated LUMIPULSE® G immunoassay analyzers. This CLEIA (chemiluminescent enzyme immunoassay) assay is available for Research Use Only (RUO) and allows for the quantitative measurement of soluble Triggering Receptor Expressed on Myeloid Cells 2 (sTREM2) in human cerebrospinal fluid (CSF) and bloo...
Back to Newsroom